Sarcopenia and Frailty in Cirrhosis

References

1. • Bunchorntavakul C.
   • Reddy K.R.
   Review article: malnutrition/sarcopenia and frailty in patients with cirrhosis.
   Aliment Pharmacol Ther. 2020; 51: 64-77
   View in Article

   • Google Scholar
2. • Lai J.C.
   • Tandon P.
   • Bernal W.
   • et al.
   Malnutrition, Frailty, and Sarcopenia in Patients With Cirrhosis: 2021 Practice Guidance by the American Association for the Study of Liver Diseases.
   Hepatology. 2021; 74: 1611-1644
   View in Article

   • Google Scholar
3. • Tandon P.
   • Montano-Loza A.J.
   • Lai J.C.
   • et al.
   Sarcopenia and frailty in decompensated cirrhosis.
   J Hepatol. 2021; 75: S147-S162
   View in Article

   • Google Scholar
4. • Nishikawa H.
   • Enomoto H.
   • Nishiguchi S.
   • et al.
   Liver Cirrhosis and Sarcopenia from the Viewpoint of Dysbiosis.
   Int J Mol Sci. 2020; 21: 5254
   View in Article

   • Google Scholar
5. • Jindal A.
   • Jagdish R.K.
   Sarcopenia: Ammonia metabolism and hepatic encephalopathy.
   Clin Mol Hepatol. 2019; 25: 270-279
   View in Article

   • Google Scholar
6. • Kawaguchi T.
   • Izumi N.
   • Charlton M.R.
   Sata M Branched-chain amino acids as pharmacological nutrients in chronic liver disease.
   Hepatology. 2011; 54: 1063-1070
   View in Article

   • Google Scholar
7. • Nishikawa H.
   • Yoh K.
   • Enomoto H.
   • et al.
   Serum Zinc Level Is Associated with Frailty in Chronic Liver Diseases.
   J Clin Med. 2020; 9: 1570
   View in Article

   • Google Scholar
8. • Wintermeyer E.
   • Ihle C.
   • Ehnert S.
   • et al.
   Crucial Role of Vitamin D in the Musculoskeletal System.
   Nutrients. 2016; 8: 319
   View in Article

   • Google Scholar
9. EASL Clinical Practice Guidelines on nutrition in chronic liver disease.
   J Hepatol. 2019; 70: 172-193
   View in Article

   • Google Scholar
10. • Lai J.C.
    • Sonnenday C.J.
    • Tapper E.B.
    • et al.
    Frailty in liver transplantation: An expert opinion statement from the American Society of Transplantation Liver and Intestinal Community of Practice.
    Am J Transplant. 2019; 19: 1896-1906
    View in Article

    • Google Scholar
11. • Georgiou A.
    • Papatheodoridis G.V.
    • Alexopoulou A.
    • et al.
    Evaluation of the effectiveness of eight screening tools in detecting risk of malnutrition in cirrhotic patients: the KIRRHOS study.
    Br J Nutr. 2019; 122: 1368-1376
    View in Article

    • Google Scholar
12. • Wu Y.
    • Zhu Y.
    • Feng Y.
    • et al.
    Royal Free Hospital-Nutritional Prioritizing Tool improves the prediction of malnutrition risk outcomes in liver cirrhosis patients compared with Nutritional Risk Screening 2002.
    Br J Nutr. 2020; 124: 1293-1302
    View in Article

    • Google Scholar
13. • Tandon P.
    • Raman M.
    • Mourtzakis M.
    • et al.
    A practical approach to nutritional screening and assessment in cirrhosis.
    Hepatology. 2017; 65: 1044-1057
    View in Article

    • Google Scholar
14. • Chen L.K.
    • Woo J.
    • Assantachai P.
    • et al.
    Asian Working Group for Sarcopenia: 2019 Consensus Update on Sarcopenia Diagnosis and Treatment.
    J Am Med Dir Assoc. 2020; 21: 300-307
    View in Article

    • Google Scholar
15. • Cruz-Jentoft A.J.
    • Bahat G.
    • Bauer J.
    • et al.
    Sarcopenia: revised European consensus on definition and diagnosis.
    Age Ageing. 2019; 48: 601
    View in Article

    • Google Scholar
16. • Yamada Y.
    • Yamada M.
    • Yoshida T.
    • et al.
    Validating muscle mass cutoffs of four international sarcopenia-working groups in Japanese people using DXA and BIA.
    J Cachexia Sarcopenia Muscle. 2021; 12: 1000-1010
    View in Article

    • Google Scholar
17. • Nishikawa H.
    • Shiraki M.
    • Hiramatsu A.
    • et al.
    Japan Society of Hepatology guidelines for sarcopenia in liver disease (1st edition): Recommendation from the working group for creation of sarcopenia assessment criteria.
    Hepatol Res. 2016; 46: 951-963
    View in Article

    • Google Scholar
18. • Ebadi M.
    • Wang C.W.
    • Lai J.C.
    • et al.
    Poor performance of psoas muscle index for identification of patients with higher waitlist mortality risk in cirrhosis.
    J Cachexia Sarcopenia Muscle. 2018; 9: 1053-1062
    View in Article

    • Google Scholar
19. • Wells C.I.
    • McCall J.L.
    • Plank L.D.
    Relationship Between Total Body Protein and Cross-Sectional Skeletal Muscle Area in Liver Cirrhosis Is Influenced by Overhydration.
    Liver Transpl. 2019; 25: 45-55
    View in Article

    • Google Scholar
20. • Carey E.J.
    • Lai J.C.
    • Wang C.W.
    • et al.
    A multicenter study to define sarcopenia in patients with end-stage liver disease.
    Liver Transpl. 2017; 23: 625-633
    View in Article

    • Google Scholar
21. • Georgiou A.
    • Papatheodoridis G.V.
    • Alexopoulou A.
    Validation of cutoffs for skeletal muscle mass index based on computed tomography analysis against dual energy X-ray absorptiometry in patients with cirrhosis: the KIRRHOS study.
    Ann Gastroenterol. 2020; 33: 80-86
    View in Article

    • Google Scholar
22. • Montano-Loza A.J.
    • Angulo P.
    • Meza-Junco J.
    • et al.
    Sarcopenic obesity and myosteatosis are associated with higher mortality in patients with cirrhosis.
    J Cachexia Sarcopenia Muscle. 2016; 7: 126-135
    View in Article

    • Google Scholar
23. • Carias S.
    • Castellanos A.L.
    • Vilchez V.
    • et al.
    Nonalcoholic steatohepatitis is strongly associated with sarcopenic obesity in patients with cirrhosis undergoing liver transplant evaluation.
    J Gastroenterol Hepatol. 2016; 31: 628-633
    View in Article

    • Google Scholar
24. • Tandon P.
    • Reddy K.R.
    • O'Leary J.G.
    • et al.
    A Karnofsky performance status-based score predicts death after hospital discharge in patients with cirrhosis.
    Hepatology. 2017; 65: 217-224
    View in Article

    • Google Scholar
25. • Thuluvath P.J.
    • Thuluvath A.J.
    • Savva Y.
    Karnofsky performance status before and after liver transplantation predicts graft and patient survival.
    J Hepatol. 2018; 69: 818-825
    View in Article

    • Google Scholar
26. • Kardashian A.
    • Ge J.
    • McCulloch C.E.
    • et al.
    Identifying an Optimal Liver Frailty Index Cutoff to Predict Waitlist Mortality in Liver Transplant Candidates.
    Hepatology. 2021; 73: 1132-1139
    View in Article

    • Google Scholar
27. • Lai J.C.
    • Covinsky K.E.
    • Dodge J.L.
    • et al.
    Development of a novel frailty index to predict mortality in patients with end-stage liver disease.
    Hepatology. 2017; 66: 564-574
    View in Article

    • Google Scholar
28. • Tandon P.
    • Ney M.
    • Irwin I.
    • et al.
    Severe muscle depletion in patients on the liver transplant wait list: its prevalence and independent prognostic value.
    Liver Transpl. 2012; 18: 209-1216
    View in Article

    • Google Scholar
29. • Merli M.
    • Riggio O.
    • Dally L.
    Does malnutrition affect survival in cirrhosis? PINC (Policentrica Italiana Nutrizione Cirrosi).
    Hepatology. 1996; 23: 1041-1046
    View in Article

    • Google Scholar
30. • Tantai X.
    • Liu Y.
    • Yeo Y.H.
    • et al.
    Effect of sarcopenia on survival in patients with cirrhosis: A meta-analysis.
    J Hepatol. 2022; 76: 588-599
    View in Article

    • Google Scholar
31. • Ooi P.H.
    • Hager A.
    • Mazurak V.C.
    • et al.
    Sarcopenia in chronic liver disease: impact on outcomes.
    Liver Transpl. 2019; 25: 1422-1438
    View in Article

    • Google Scholar
32. • Jeon J.Y.
    • Wang H.J.
    • Ock S.Y.
    • et al.
    Newly developed sarcopenia as a prognostic factor for survival in patients who underwent liver transplantation.
    PLoS One. 2015; 10: e0143966
    View in Article

    • Google Scholar
33. • Kaido T.
    • Tamai Y.
    • Hamaguchi Y.
    • et al.
    Effects of pretransplant sarcopenia and sequential changes in sarcopenic parameters after living donor liver transplantation.
    Nutrition. 2017; 33: 195-198
    View in Article

    • Google Scholar
34. • Tsien C.
    • Garber A.
    • Narayanan A.
    • et al.
    Post-liver transplantation sarcopenia in cirrhosis: a prospective evaluation.
    J Gastroenterol Hepatol. 2014; 29: 1250-1257
    View in Article

    • Google Scholar
35. • Bergerson J.T.
    • Lee J.G.
    • Furlan A.
    • et al.
    Liver transplantation arrests and reverses muscle wasting.
    Clin Transplant. 2015; 29: 216-221
    View in Article

    • Google Scholar
36. • Lai J.C.
    • Rahimi R.S.
    • Verna E.C.
    • et al.
    Frailty associated with waitlist mortality independent of ascites and hepatic encephalopathy in a multicenter study.
    Gastroenterology. 2019; 156: 1675-1682
    View in Article

    • Google Scholar
37. • Tapper E.
    • Baki J.
    • Parikh N.D.
    • et al.
    Frailty, Psychoactive medications, and cognitive dysfunction are associated with poor patient-reported outcomes in cirrhosis.
    Hepatology. 2019; 69: 1676-1685
    View in Article

    • Google Scholar
38. • Tapper E.B.
    • Finkelstein D.
    • Mittleman M.A.
    • et al.
    Standard assessments of frailty are validated predictors of mortality in hospitalized patients with cirrhosis.
    Hepatology. 2015; 62: 584-590
    View in Article

    • Google Scholar
39. • Lai J.C.
    • Ganger D.R.
    • Volk M.L.
    • et al.
    Association of frailty and sex with wait list mortality in liver transplant candidates in the multicenter functional assessment in liver transplantation (FrAILT) study.
    JAMA Surg. 2021; 156: 256-262
    View in Article

    • Google Scholar
40. • Lai J.C.
    • Segev D.L.
    • McCulloch C.E.
    • et al.
    Physical frailty after liver transplantation.
    Am J Transplant. 2018; 18: 1986-1994
    View in Article

    • Google Scholar
41. • Lai J.C.
    • Dodge J.L.
    • Kappus M.R.
    • et al.
    Changes in frailty are associated with waitlist mortality in patients with cirrhosis.
    J Hepatol. 2020; 73: 575-581
    View in Article

    • Google Scholar
42. • Cron D.C.
    • Friedman J.F.
    • Winder G.S.
    • et al.
    Depression and frailty in patients with end-stage liver disease referred for transplant evaluation.
    Am J Transplant. 2016; 16: 1805-1811
    View in Article

    • Google Scholar
43. • Lai J.C.
    • Dodge J.L.
    • McCulloch C.E.
    • et al.
    Frailty and the burden of concurrent and incident disability in patients with cirrhosis: a prospective cohort study.
    Hepatol Commun. 2019; 4: 126-133
    View in Article

    • Google Scholar
44. • Tapper E.B.
    • Nikirk S.
    • Parikh N.D.
    • et al.
    Falls are common, morbid, and predictable in patients with cirrhosis.
    J Hepatol. 2021; 75: 582-588
    View in Article

    • Google Scholar
45. • Tapper E.B.
    • Zhao L.
    • Nikirk S.
    • et al.
    Incidence and bedside predictors of the first episode of overt hepatic encephalopathy in patients with cirrhosis.
    Am J Gastroenterol. 2020; 115: 2017-2025
    View in Article

    • Google Scholar
46. • Yadav A.
    • Chang Y.H.
    • Carpenter S.
    • et al.
    Relationship between sarcopenia, six-minute walk distance and health-related quality of life in liver transplant candidates.
    Clin Transplant. 2015; 29: 134-141
    View in Article

    • Google Scholar
47. • Allard J.P.
    • Chau J.
    • Sandokji K.
    • et al.
    Effects of ascites resolution after successful TIPS on nutrition in cirrhotic patients with refractory ascites.
    Am J Gastroenterol. 2001; 96: 2442-2447
    View in Article

    • Google Scholar
48. • Artru F.
    • Miquet X.
    • Azahaf M.
    • et al.
    Consequences of TIPSS placement on the body composition of patients with cirrhosis and severe portal hypertension: a large retrospective CT-based surveillance.
    Aliment Pharmacol Ther. 2020; 52: 1516-1526
    View in Article

    • Google Scholar
49. • Benmassaoud A.
    • Roccarina D.
    • Arico F.
    • et al.
    Sarcopenia does not worsen survival in patients with cirrhosis undergoing transjugular intrahepatic portosystemic shunt for refractory ascites.
    Am J Gastroenterol. 2020; 115: 1911-1914
    View in Article

    • Google Scholar
50. • Tsien C.
    • Shah S.N.
    • McCullough A.J.
    • et al.
    Reversal of sarcopenia predicts survival after a transjugular intrahepatic portosystemic stent.
    Eur J Gastroenterol Hepatol. 2013; 25: 85-93
    View in Article

    • Google Scholar
51. • Kumar A.
    • Davuluri G.
    • Silva R.N.E.
    • et al.
    Ammonia lowering reverses sarcopenia of cirrhosis by restoring skeletal muscle proteostasis.
    Hepatology. 2017; 65: 2045-2058
    View in Article

    • Google Scholar
52. • Sinclair M.
    • Gow P.J.
    • Grossmann M.
    • et al.
    Review article: sarcopenia in cirrhosis--aetiology, implications and potential therapeutic interventions.
    Aliment Pharmacol Ther. 2016; 43: 765-777
    View in Article

    • Google Scholar
53. • Hanai T.
    • Shiraki M.
    • Imai K.
    • et al.
    Usefulness of carnitine supplementation for the complications of liver cirrhosis.
    Nutrients. 2020; 12: 1915
    View in Article

    • Google Scholar
54. • Malaguarnera M.
    • Vacante M.
    • Giordano M.
    • et al.
    Oral acetyl-L-carnitine therapy reduces fatigue in overt hepatic encephalopathy: a randomized, double-blind, placebo-controlled study.
    Am J Clin Nutr. 2011; 93: 799-808
    View in Article

    • Google Scholar
55. • Hiramatsu A.
    • Aikata H.
    • Uchikawa S.
    • et al.
    Levocarnitine use is associated with improvement in sarcopenia in patients with liver cirrhosis.
    Hepatol Commun. 2019; 3: 348-355
    View in Article

    • Google Scholar
56. • Ohara M.
    • Ogawa K.
    • Suda G.
    • et al.
    L-Carnitine suppresses loss of skeletal muscle mass in patients with liver cirrhosis.
    Hepatol Commun. 2018; 2: 906-918
    View in Article

    • Google Scholar
57. • Martí-Carvajal A.J.
    • Gluud C.
    • Arevalo-Rodriguez I.
    • et al.
    Acetyl-L-carnitine for patients with hepatic encephalopathy.
    Cochrane Database Syst Rev. 2019; 1: CD011451
    View in Article

    • Google Scholar
58. • Córdoba J.
    • López-Hellín J.
    • Planas M.
    Normal protein diet for episodic hepatic encephalopathy: results of a randomized study.
    J Hepatol. 2004; 41: 38-43
    View in Article

    • Google Scholar
59. • Greco A.V.
    • Mingrone G.
    • Benedetti G.
    • et al.
    Daily energy and substrate metabolism in patients with cirrhosis.
    Hepatology. 1998; 27: 346-350
    View in Article

    • Google Scholar
60. • Chen C.J.
    • Wang L.C.
    • Kuo H.T.
    • et al.
    Significant effects of late evening snack on liver functions in patients with liver cirrhosis: a meta-analysis of randomized controlled trials.
    J Gastroenterol Hepatol. 2019; 34: 1143-1152
    View in Article

    • Google Scholar
61. • Plank L.D.
    • Gane E.J.
    • Peng S.
    • et al.
    Nocturnal nutritional supplementation improves total body protein status of patients with liver cirrhosis: a randomized 12-month trial.
    Hepatology. 2008; 48: 557-566
    View in Article

    • Google Scholar
62. • Tsien C.D.
    • McCullough A.J.
    • Dasarathy S.
    Late evening snack: exploiting a period of anabolic opportunity in cirrhosis.
    J Gastroenterol Hepatol. 2012; 27: 430-441
    View in Article

    • Google Scholar
63. • Morando F.
    • Rosi S.
    • Gola E.
    • et al.
    Adherence to a moderate sodium restriction diet in outpatients with cirrhosis and ascites: a real-life cross-sectional study.
    Liver Int. 2015; 35: 1508-1515
    View in Article

    • Google Scholar
64. • Holecek M.
    Three targets of branched-chain amino acid supplementation in the treatment of liver disease.
    Nutrition. 2010; 26: 482-490
    View in Article

    • Google Scholar
65. • Marchesini G.
    • Bianchi G.
    • Merli M.
    • et al.
    Nutritional supplementation with branched-chain amino acids in advanced cirrhosis: a double-blind, randomized trial.
    Gastroenterology. 2003; 124: 1792-1801
    View in Article

    • Google Scholar
66. • Muto Y.
    • Sato S.
    • Watanabe A.
    • et al.
    Effects of oral branched-chain amino acid granules on event-free survival in patients with liver cirrhosis.
    Clin Gastroenterol Hepatol. 2005; 3: 705-713
    View in Article

    • Google Scholar
67. • Les I.
    • Doval E.
    • García-Martínez R.
    • et al.
    Effects of branched-chain amino acids supplementation in patients with cirrhosis and a previous episode of hepatic encephalopathy: a randomized study.
    Am J Gastroenterol. 2011; 106: 1081-1088
    View in Article

    • Google Scholar
68. • Kawaguchi T.
    • Shiraishi K.
    • Ito T.
    • et al.
    Branched-chain amino acids prevent hepatocarcinogenesis and prolong survival of patients with cirrhosis.
    Clin Gastroenterol Hepatol. 2014; 12: 1012-1018
    View in Article

    • Google Scholar
69. • Ooi P.H.
    • Gilmour S.M.
    • Yap J.
    • et al.
    Effects of branched chain amino acid supplementation on patient care outcomes in adults and children with liver cirrhosis: A systematic review.
    Clin Nutr ESPEN. 2018; 28: 41-51
    View in Article

    • Google Scholar
70. • Ismaiel A.
    • Bucsa C.
    • Farcas A.
    • et al.
    Effects of branched-chain amino acids on parameters evaluating sarcopenia in liver cirrhosis: systematic review and meta-analysis.
    Front Nutr. 2022; 9: 1-3
    View in Article

    • Google Scholar
71. • Gluud L.L.
    • Dam G.
    • Les I.
    • et al.
    Branched-chain amino acids for people with hepatic encephalopathy.
    Cochrane Database Syst Rev. 2015; 9: CD001939
    View in Article

    • Google Scholar
72. • Plauth M.
    • Bernal W.
    • Dasarathy S.
    • et al.
    ESPEN guideline on clinical nutrition in liver disease.
    Clin Nutr ESPEN. 2019; 38: 485-521
    View in Article

    • Google Scholar
73. • Warner 2nd, E.R.
    • Aloor F.Z.
    • Satapathy S.K.
    A narrative review of nutritional abnormalities, complications, and optimization in the cirrhotic patient.
    Transl Gastroenterol Hepatol. 2022; 7: 5
    View in Article

    • Google Scholar
74. • Rossi R.E.
    • Conte D.
    • Massironi S.
    Diagnosis and treatment of nutritional deficiencies in alcoholic liver disease: Overview of available evidence and open issues.
    Dig Liver Dis. 2015; 47: 819-825
    View in Article

    • Google Scholar
75. • Wu J.
    • Meng Q.H.
    Current understanding of the metabolism of micronutrients in chronic alcoholic liver disease.
    World J Gastroenterol. 2020; 26: 4567-4578
    View in Article

    • Google Scholar
76. • Jorgensen R.A.
    • Lindor K.D.
    • Sartin J.S.
    • et al.
    Serum lipid and fat-soluble vitamin levels in primary sclerosing cholangitis.
    J Clin Gastroenterol. 1995; 20: 215-219
    View in Article

    • Google Scholar
77. • Phillips J.R.
    • Angulo P.
    • Petterson T.
    • et al.
    Fat-soluble vitamin levels in patients with primary biliary cirrhosis.
    Am J Gastroenterol. 2001; 96: 2745-2750
    View in Article

    • Google Scholar
78. • Aagaard N.K.
    • Andersen H.
    • Vilstrup H.
    • et al.
    Decreased muscle strength and contents of Mg and Na,K-pumps in chronic alcoholics occur independently of liver cirrhosis.
    J Intern Med. 2003; 253: 359-366
    View in Article

    • Google Scholar
79. • Aagaard N.K.
    • Andersen H.
    • Vilstrup H.
    • et al.
    Muscle strength, Na,K-pumps, magnesium and potassium in patients with alcoholic liver cirrhosis -- relation to spironolactone.
    J Intern Med. 2002; 252: 56-63
    View in Article

    • Google Scholar
80. • Rocchi E.
    • Borella P.
    • Borghi A.
    • et al.
    Zinc and magnesium in liver cirrhosis.
    Eur J Clin Invest. 1994; 24: 149-155
    View in Article

    • Google Scholar
81. • Heubi J.E.
    • Higgins J.V.
    • Argao E.A.
    • et al.
    The role of magnesium in the pathogenesis of bone disease in childhood cholestatic liver disease: a preliminary report.
    J Pediatr Gastroenterol Nutr. 1997; 25: 301-306
    View in Article

    • Google Scholar
82. • Grüngreiff K.
    • Reinhold D.
    • Wedemeyer H.
    The role of zinc in liver cirrhosis.
    Ann Hepatol. 2016; 15: 7-16
    View in Article

    • Google Scholar
83. • Mohammad M.K.
    • Zhou Z.
    • Cave M.
    • et al.
    Zinc and liver disease.
    Nutr Clin Pract. 2012; 27: 8-20
    View in Article

    • Google Scholar
84. • Okubo T.
    • Atsukawa M.
    • Tsubota A.
    • et al.
    Effect of Vitamin D supplementation on skeletal muscle volume and strength in patients with decompensated liver cirrhosis undergoing branched chain amino acids supplementation: a prospective, randomized, controlled pilot trial.
    Nutrients. 2021; 13: 1874
    View in Article

    • Google Scholar
85. • de Lédinghen V.
    • Beau P.
    • Mannant P.R.
    • et al.
    Early feeding or enteral nutrition in patients with cirrhosis after bleeding from esophageal varices? A randomized controlled study.
    Dig Dis Sci. 1996; 42: 536-541
    View in Article

    • Google Scholar
86. • Sidhu S.S.
    • Goyal O.
    • Singh S.
    • et al.
    Early feeding after esophageal variceal band ligation in cirrhotics is safe: Randomized controlled trial.
    Dig Endosc. 2019; 31: 646-652
    View in Article

    • Google Scholar
87. • Fialla A.D.
    • Israelsen M.
    • Hamberg O.
    • et al.
    Nutritional therapy in cirrhosis or alcoholic hepatitis: a systematic review and meta-analysis.
    Liver Int. 2015; 35: 2072-2078
    View in Article

    • Google Scholar
88. • Berzigotti A.
    • Albillos A.
    • Villanueva C.
    • et al.
    Effects of an intensive lifestyle intervention program on portal hypertension in patients with cirrhosis and obesity: The SportDiet study.
    Hepatology. 2017; 65: 1293-1305
    View in Article

    • Google Scholar
89. • Duarte-Rojo A.
    • Ruiz-Margáin A.
    • Montaño-Loza A.J.
    • et al.
    Exercise and physical activity for patients with end-stage liver disease: Improving functional status and sarcopenia while on the transplant waiting list.
    Liver Transpl. 2018; 24: 122-139
    View in Article

    • Google Scholar
90. • Kruger C.
    • McNeely M.L.
    • Bailey R.J.
    • et al.
    Home exercise training improves exercise capacity in cirrhosis patients: role of exercise adherence.
    Sci Rep. 2018; 8: 99
    View in Article

    • Google Scholar
91. • Tandon P.
    • Ismond K.P.
    • Riess K.
    • et al.
    Exercise in cirrhosis: translating evidence and experience to practice.
    J Hepatol. 2018; 69: 1164-1177
    View in Article

    • Google Scholar
92. • Williams F.R.
    • Berzigotti A.
    • Lord J.M.
    • et al.
    Review article: impact of exercise on physical frailty in patients with chronic liver disease.
    Aliment Pharmacol Ther. 2019; 50: 988-1000
    View in Article

    • Google Scholar
93. • Zenith L.
    • Meena N.
    • Ramadi A.
    • et al.
    Eight weeks of exercise training increases aerobic capacity and muscle mass and reduces fatigue in patients with cirrhosis.
    Clin Gastroenterol Hepatol. 2014; 12: 1920-1926
    View in Article

    • Google Scholar
94. • Moctezuma-Velázquez C.
    • Low G.
    • Mourtzakis M.
    • et al.
    Association between low testosterone levels and sarcopenia in cirrhosis: a cross-sectional study.
    Ann Hepatol. 2018; 17: 615-623
    View in Article

    • Google Scholar
95. • Sinclair M.
    • Gow P.J.
    • Grossmann M.
    • et al.
    Low serum testosterone is associated with adverse outcome in men with cirrhosis independent of the model for end-stage liver disease score.
    Liver Transpl. 2016; 22: 1482-1490
    View in Article

    • Google Scholar
96. • Sinclair M.
    • Grossmann M.
    • Gow P.
    • et al.
    Testosterone in men with advanced liver disease: abnormalities and implications.
    J Gastroenterol Hepatol. 2015; 30: 244-251
    View in Article

    • Google Scholar
97. • Rambaldi A.
    • Gluud C.
    Anabolic-androgenic steroids for alcoholic liver disease.
    Cochrane Database Syst Rev. 2006; 2006: CD003045
    View in Article

    • Google Scholar
98. • Yurci A.
    • Yucesoy M.
    • Unluhizarci K.
    • et al.
    Effects of testosterone gel treatment in hypogonadal men with liver cirrhosis.
    Clin Res Hepatol Gastroenterol. 2011; 35: 845-854
    View in Article

    • Google Scholar
99. • Sinclair M.
    • Grossmann M.
    • Hoermann R.
    • et al.
    Testosterone therapy increases muscle mass in men with cirrhosis and low testosterone: A randomised controlled trial.
    J Hepatol. 2016; 65: 906-913
    View in Article

    • Google Scholar
100. • Grech A.
     • Breck J.
     • Heidelbaugh J.
     Adverse effects of testosterone replacement therapy: an update on the evidence and controversy.
     Ther Adv Drug Saf. 2014; 5: 190-200
     View in Article

     • Google Scholar
101. • Johnson F.L.
     • Lerner K.G.
     • Siegel M.
     • et al.
     Association of androgenic-anabolic steroid therapy with development of hepatocellular carcinoma.
     Lancet. 1972; 2: 1273-1276
     View in Article

     • Google Scholar